(19)
(11) EP 4 824 287 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24904900.8

(22) Date of filing: 12.12.2024
(51) International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
C07K 16/30(2006.01)
(52) Cooperative Patent Classification (CPC):
C12Q 1/6886; C07K 16/2875; A61K 40/4232; A61K 40/11; A61K 40/31; A61K 31/519; A61K 31/517; A61K 31/4545; A61K 31/675; A61K 45/06; A61K 47/68031; A61K 47/6851; C12Q 2600/106; C12Q 2600/158; C12Q 2600/156
 
C-Sets:
  1. A61K 31/519, A61K 2300/00;
  2. A61K 31/517, A61K 2300/00;
  3. A61K 31/4545, A61K 2300/00;
  4. A61K 31/675, A61K 2300/00;

(86) International application number:
PCT/US2024/059869
(87) International publication number:
WO 2025/128880 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 15.12.2023 US 202363610941 P

(71) Applicant: Board of Regents, The University of Texas System
Austin, TX 78701 (US)

(72) Inventors:
  • HEYMACH, John Victor
    Austin, Texas 78701 (US)
  • NILSSON, Monique B.
    Austin, Texas 78701 (US)

(74) Representative: Atkins, James Gordon John et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)

   


(54) CD70 TARGETING IN CANCER WITH ACQUIRED RESISTANCE TO TARGETED THERAPEUTIC AGENTS